Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action
Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multip...
Uložené v:
| Vydané v: | Current controlled trials in cardiovascular medicine Ročník 22; číslo 1; s. 880 - 11 |
|---|---|
| Hlavní autori: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
04.12.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these.
Methods
A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded.
Results
Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [
1
] a multi-faceted approach is essential [
2
]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers.
Conclusions
Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population’s particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. |
|---|---|
| AbstractList | BackgroundWithout inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these.MethodsA rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded.ResultsSeventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers.ConclusionsMany of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population’s particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Abstract Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these. Methods A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded. Results Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers. Conclusions Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population’s particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these. Methods A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded. Results Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [ 1 ] a multi-faceted approach is essential [ 2 ]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers. Conclusions Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population’s particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these.BACKGROUNDWithout inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these.A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded.METHODSA rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded.Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers.RESULTSSeventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers.Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population's particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings.CONCLUSIONSMany of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population's particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these. A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded. Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers. Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population's particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these. Methods A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded. Results Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers. Conclusions Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population's particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Keywords: Equality, Diversity, Inclusion, Ethnicity, Clinical research, Clinical trial, Review |
| ArticleNumber | 880 |
| Audience | Academic |
| Author | Lawson, Claire Zaccardi, Francesco Willis, Andrew Gillies, Clare Yates, Thomas Khunti, Kamlesh Routen, Ash C. Davies, Melanie J. Bodicoat, Danielle H. Ekezie, Winifred |
| Author_xml | – sequence: 1 givenname: Danielle H. surname: Bodicoat fullname: Bodicoat, Danielle H. organization: Independent Researcher – sequence: 2 givenname: Ash C. orcidid: 0000-0001-5651-4228 surname: Routen fullname: Routen, Ash C. organization: Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 3 givenname: Andrew surname: Willis fullname: Willis, Andrew organization: Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 4 givenname: Winifred surname: Ekezie fullname: Ekezie, Winifred organization: Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 5 givenname: Clare surname: Gillies fullname: Gillies, Clare organization: Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 6 givenname: Claire surname: Lawson fullname: Lawson, Claire organization: Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 7 givenname: Thomas surname: Yates fullname: Yates, Thomas organization: Diabetes Research Centre, University of Leicester, Leicester General Hospital, NIHR Leicester Biomedical Research Centre, Leicester General Hospital – sequence: 8 givenname: Francesco surname: Zaccardi fullname: Zaccardi, Francesco organization: Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital – sequence: 9 givenname: Melanie J. surname: Davies fullname: Davies, Melanie J. organization: Diabetes Research Centre, University of Leicester, Leicester General Hospital, NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust – sequence: 10 givenname: Kamlesh surname: Khunti fullname: Khunti, Kamlesh email: kk22@leicester.ac.uk organization: Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Diabetes Research Centre, University of Leicester, Leicester General Hospital, NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital |
| BookMark | eNp9kstu1DAUhiNURC_wAqwssWGT4nucDVJVcalUCRawthz7ZMajxB5sp4gdD8ET8iR4OkVlKlRl4SP7_7-jc_KfNkchBmialwSfE6Lkm0wYlqzFlLRYKN633ZPmhHRctJIScfRPfdyc5rzBmLOe8WfNMeNKMirFSbP-nOIciw8r5IOdluxjqBWykw_emgmV5M2Uf__8ZVAyW-9QghsP31EcUVkDmnyBZMqSAJmwe7RxniE4UyooozEmZOyuft48HSsIXtydZ83X9---XH5srz99uLq8uG5tHaG0AtuODcPAFbNdD2xgHMahE2wUVnScgXDUGW4VJh3j0nLpiHOC01ERRgGzs-Zqz3XRbPQ2-dmkHzoar28vYlppk4q3E2gYHJG1E8Gy55JLBYxQ3veWWDMwISvr7Z61XYYZnIVQkpkOoIcvwa_1Kt5oJTkjilfA6ztAit8WyEXPPluYJhMgLllTiTuGBeO0Sl89kG7ikkJdlaaKUEZVR_C9amXqAD6Msfa1O6i-kLUrrTsSVXX-H1X9HMze1hCNvt4fGNTeYFPMOcGorS-3v7Aa_aQJ1rvE6X3idE2cvk2c7qqVPrD-Xc-jJrY35SoOK0j3wz7i-gNY6elI |
| CitedBy_id | crossref_primary_10_1136_bmjmed_2024_000984 crossref_primary_10_1016_j_jval_2024_09_012 crossref_primary_10_1038_s41591_024_03273_3 crossref_primary_10_1177_01410768231187734 crossref_primary_10_1007_s43441_025_00751_9 crossref_primary_10_1016_j_radi_2023_04_006 crossref_primary_10_1038_s41582_025_01115_5 crossref_primary_10_3389_fpsyt_2024_1448487 crossref_primary_10_36128_priw_vi41_421 crossref_primary_10_1136_bmjonc_2023_000092 crossref_primary_10_2105_AJPH_2023_307385 crossref_primary_10_1016_j_glmedi_2025_100203 crossref_primary_10_1136_bmjopen_2024_087627 crossref_primary_10_2196_65489 crossref_primary_10_1038_s41591_023_02675_z crossref_primary_10_1186_s12939_025_02431_4 crossref_primary_10_1016_j_jclinepi_2025_111922 crossref_primary_10_1093_eurjcn_zvae002 crossref_primary_10_1017_cts_2024_13 crossref_primary_10_1136_bmjopen_2024_095778 crossref_primary_10_1186_s12916_023_02809_7 crossref_primary_10_1016_j_jdin_2023_11_009 crossref_primary_10_1016_j_cct_2022_107064 crossref_primary_10_1001_jamacardio_2025_2421 crossref_primary_10_1016_j_glmedi_2025_100211 crossref_primary_10_1371_journal_pone_0315506 crossref_primary_10_1007_s40615_025_02377_x crossref_primary_10_1177_17407745241302477 crossref_primary_10_1542_neo_24_8_e504 crossref_primary_10_1186_s13063_024_08108_7 crossref_primary_10_2478_jhp_2022_0007 crossref_primary_10_1016_j_jclinepi_2024_111259 crossref_primary_10_1038_s41591_023_02665_1 crossref_primary_10_3390_cancers17020225 crossref_primary_10_1007_s40290_022_00458_4 crossref_primary_10_1093_eurjcn_zvaf007 crossref_primary_10_1093_crocol_otae019 crossref_primary_10_1016_j_pedhc_2025_02_007 crossref_primary_10_1007_s10555_024_10187_6 crossref_primary_10_1007_s12671_025_02631_7 crossref_primary_10_1186_s40337_023_00846_4 crossref_primary_10_3390_ijerph21040449 crossref_primary_10_1016_j_puhe_2024_05_007 crossref_primary_10_1016_j_tranon_2025_102493 crossref_primary_10_1186_s13063_022_06747_2 crossref_primary_10_1186_s13063_024_07944_x crossref_primary_10_12688_f1000research_161505_3 crossref_primary_10_12688_f1000research_161505_1 crossref_primary_10_12688_f1000research_161505_2 crossref_primary_10_2196_37567 crossref_primary_10_1186_s13063_025_08803_z crossref_primary_10_1016_j_jclinepi_2024_111649 crossref_primary_10_1016_j_msard_2023_104606 crossref_primary_10_1186_s12910_025_01211_7 crossref_primary_10_1089_aid_2024_0117 crossref_primary_10_1186_s40900_024_00600_3 crossref_primary_10_1111_hex_13944 crossref_primary_10_1186_s13063_024_08150_5 crossref_primary_10_1186_s13063_025_08893_9 crossref_primary_10_1186_s12875_023_02221_3 crossref_primary_10_1038_s41598_023_27416_7 crossref_primary_10_2196_42967 crossref_primary_10_1161_STROKEAHA_124_046958 crossref_primary_10_1016_j_jclinepi_2024_111315 crossref_primary_10_1002_cam4_71071 crossref_primary_10_1136_bmjopen_2024_084678 crossref_primary_10_1161_JAHA_123_033467 crossref_primary_10_1371_journal_pone_0282088 crossref_primary_10_1007_s11060_025_05180_0 crossref_primary_10_1016_j_apmr_2025_03_043 crossref_primary_10_1177_13524585231189677 crossref_primary_10_1177_15394492231225199 crossref_primary_10_1177_26320843241296076 crossref_primary_10_1186_s13063_024_08487_x crossref_primary_10_1186_s12875_024_02610_2 crossref_primary_10_1093_ehjqcco_qcaf007 crossref_primary_10_1186_s40900_024_00647_2 crossref_primary_10_1186_s13063_025_08820_y crossref_primary_10_2196_67469 crossref_primary_10_1186_s13063_022_06553_w crossref_primary_10_1016_j_hctj_2025_100112 crossref_primary_10_1111_dme_15024 crossref_primary_10_1111_epi_17716 crossref_primary_10_1007_s11886_023_01942_2 crossref_primary_10_1513_AnnalsATS_202312_1074OC crossref_primary_10_1002_pits_23554 crossref_primary_10_1177_1358863X231154951 crossref_primary_10_1186_s13063_024_08471_5 crossref_primary_10_1080_03007995_2025_2465618 crossref_primary_10_1007_s11121_025_01810_1 crossref_primary_10_1093_ndt_gfae210 crossref_primary_10_3389_fpubh_2024_1417684 crossref_primary_10_3389_fresc_2023_1085658 crossref_primary_10_1159_000541935 crossref_primary_10_1007_s00520_023_08301_5 crossref_primary_10_1016_j_cjca_2024_01_028 crossref_primary_10_1186_s12939_024_02104_8 crossref_primary_10_1093_jnci_djad013 crossref_primary_10_1001_jamapediatrics_2022_0139 crossref_primary_10_1177_15248380221130354 crossref_primary_10_7326_M23_0768 crossref_primary_10_12968_bjon_2023_32_18_898 crossref_primary_10_1186_s40900_023_00539_x crossref_primary_10_1038_s41591_024_03323_w crossref_primary_10_1016_j_jgo_2025_102304 crossref_primary_10_1177_03085759251315749 crossref_primary_10_3390_clinpract13060133 crossref_primary_10_1080_07853890_2025_2516694 crossref_primary_10_1038_s44222_023_00127_4 crossref_primary_10_1111_jep_14263 crossref_primary_10_1016_j_ygyno_2022_08_008 crossref_primary_10_2147_OAJCT_S490350 crossref_primary_10_1016_j_ejpb_2024_114510 crossref_primary_10_1136_rmdopen_2024_004246 crossref_primary_10_1186_s12875_023_02246_8 crossref_primary_10_1055_a_2648_3203 crossref_primary_10_1111_epi_18197 crossref_primary_10_1136_bmjopen_2023_075547 crossref_primary_10_1159_000540696 crossref_primary_10_1186_s13063_024_08625_5 crossref_primary_10_1111_hex_70210 crossref_primary_10_1242_dmm_050048 crossref_primary_10_3390_toxics11080655 |
| Cites_doi | 10.1177/1740774516631735 10.1177/1740774510396742 10.1177/1932296819839503 10.2196/jmir.6515 10.1001/archinte.162.15.1682 10.1007/s40266-014-0168-2 10.1016/j.jinf.2020.11.004 10.1089/jwh.2010.2504 10.1016/bs.acr.2016.08.004 10.1016/j.amepre.2015.07.036 10.1016/S0140-6736(20)31380-5 10.1093/cid/ciu726 10.1186/s12913-019-4721-x 10.1177/1073274818773720 10.1634/theoncologist.2018-0033 10.1093/deafed/enw066 10.1080/08880018.2020.1759738 10.1002/cncr.32487 10.1016/j.jvn.2018.03.003 10.1136/bmj.326.7401.1244 10.1016/j.cct.2012.06.005 10.1089/jwh.2012.3733 10.1186/s13063-018-2507-9 10.1186/s13063-016-1724-3 10.1186/s12905-016-0319-1 10.1016/S0027-9684(15)30438-7 10.1186/1475-9276-12-44 10.1177/1740774513518849 10.1177/1740774514556551 10.1634/theoncologist.2011-0384 10.1016/j.eclinm.2020.100404 10.1093/hsw/hlt001 10.1007/s40615-015-0192-x 10.1161/STROKEAHA.114.008564 10.1200/JOP.18.00638 10.2105/AJPH.2009.162982 10.1002/cncr.30935 10.1634/theoncologist.2019-0166 10.1016/j.jana.2010.10.007 10.1186/s13063-020-04613-7 10.6004/jnccn.2017.7005 10.1016/j.cct.2013.03.007 10.1186/s13063-015-0582-8 10.1016/j.vaccine.2014.03.081 10.1080/15402002.2018.1518230 10.3109/00952990.2011.596973 10.1111/hex.12984 10.1136/heart.89.3.327 10.1111/hex.12597 10.2196/14203 10.1371/journal.pone.0251685 10.1111/j.1475-6773.2012.01386.x 10.1200/JOP.2015.005934 10.1097/QAI.0000000000001085 10.1055/s-0038-1625964 10.1016/j.cct.2014.08.004 10.1177/1740774513494880 10.1186/s13063-016-1384-3 10.1186/s12889-020-08939-4 10.1089/apc.2020.0008 10.1007/s00520-018-4337-4 10.1177/0272989X13497264 10.1177/1740774512436881 10.1016/j.cpcardiol.2018.11.002 10.1093/pubmed/fdq100 10.1016/j.jad.2015.06.046 10.1007/s10900-014-9924-9 10.1016/j.jclinane.2017.08.014 10.1038/s41436-019-0498-x 10.1177/1363459320963431 10.18865/ed.29.1.23 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021. The Author(s). |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021. The Author(s). |
| DBID | C6C AAYXX CITATION 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-021-05849-7 |
| DatabaseName | Springer Nature Link CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Open Access资源_DOAJ url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_ebd16b48106946468e312499c1cab356 PMC8643184 A686425745 10_1186_s13063_021_05849_7 |
| GeographicLocations | United Kingdom United States--US |
| GeographicLocations_xml | – name: United Kingdom – name: United States--US |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c584t-50c73bbb483c79e3b34efb753f5c5743e5d2da4c8017346c46d1dd542f8132e03 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 128 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000726280200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Mon Nov 10 04:35:58 EST 2025 Tue Nov 04 01:55:45 EST 2025 Thu Oct 02 10:50:25 EDT 2025 Sun Oct 19 01:30:47 EDT 2025 Tue Nov 11 10:21:17 EST 2025 Tue Nov 04 18:04:21 EST 2025 Tue Nov 18 22:26:22 EST 2025 Sat Nov 29 06:09:56 EST 2025 Sat Sep 06 07:26:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Ethnicity Inclusion Diversity Clinical research Clinical trial Equality Review |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c584t-50c73bbb483c79e3b34efb753f5c5743e5d2da4c8017346c46d1dd542f8132e03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Literature Review-2 ObjectType-Feature-3 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-5651-4228 |
| OpenAccessLink | https://doaj.org/article/ebd16b48106946468e312499c1cab356 |
| PMID | 34863265 |
| PQID | 2812328710 |
| PQPubID | 44365 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ebd16b48106946468e312499c1cab356 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8643184 proquest_miscellaneous_2607305342 proquest_journals_2812328710 gale_infotracmisc_A686425745 gale_infotracacademiconefile_A686425745 crossref_citationtrail_10_1186_s13063_021_05849_7 crossref_primary_10_1186_s13063_021_05849_7 springer_journals_10_1186_s13063_021_05849_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-04 |
| PublicationDateYYYYMMDD | 2021-12-04 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-04 day: 04 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | 5849_CR18 C Bartlett (5849_CR4) 2003; 89 LK Rooney (5849_CR16) 2011; 33 TM Ramsey (5849_CR64) 2016; 13 5849_CR53 J Koziol-McLain (5849_CR69) 2016; 18 LT Clark (5849_CR22) 2019; 44 C Heller (5849_CR49) 2014; 39 KA Hoffman (5849_CR24) 2019; 19 H Iqbal (5849_CR9) 2021; 16 C Duda (5849_CR52) 2011; 8 JM Sacheck (5849_CR57) 2015; 12 JA Hughson (5849_CR15) 2016; 17 A Vander Stoep (5849_CR67) 2013; 10 SE Brooks (5849_CR38) 2015; 11 T Gardiner (5849_CR7) 2020; 82 5849_CR28 D Pan (5849_CR10) 2020; 23 SM Fischer (5849_CR20) 2017; 15 AJ Caldieraro-Bentley (5849_CR32) 2018; 36 V Lavender (5849_CR60) 2019; 27 M Webb Hooper (5849_CR34) 2019; 29 LP Zimmerman (5849_CR58) 2018; 9 BC Tilley (5849_CR71) 2012; 9 MD Witham (5849_CR11) 2020; 21 RA Freedman (5849_CR72) 2018; 23 CG Jennings (5849_CR74) 2015; 16 W Waheed (5849_CR42) 2015; 185 B Boden-Albala (5849_CR19) 2015; 46 NJ Barrett (5849_CR29) 2020; 126 GE Lee (5849_CR25) 2016; 16 D De las Nueces (5849_CR55) 2012; 47 AK Burlew (5849_CR54) 2011; 37 LE Wisk (5849_CR66) 2019; 13 WD Hall (5849_CR6) 1999; 9 5849_CR33 5849_CR2 R Harrison (5849_CR12) 2020; 23 F Bloch (5849_CR26) 2014; 31 CR Horowitz (5849_CR43) 2019; 21 SB Bass (5849_CR13) 2020; 34 SH Javid (5849_CR27) 2012; 17 SH Yu (5849_CR73) 2020; 18 S Treweek (5849_CR1) 2020; 395 D Rivers (5849_CR30) 2013; 35 MA Maar (5849_CR51) 2019; 21 ML Anderson (5849_CR17) 2017; 22 J Barnett (5849_CR59) 2012; 33 JM Regnante (5849_CR40) 2019; 15 F Canouï-Poitrine (5849_CR31) 2019; 24 G Kaur (5849_CR35) 2016; 17 S Mason (5849_CR3) 2003; 326 MM Byrne (5849_CR14) 2014; 34 KM Sturgeon (5849_CR65) 2018; 124 JH Wang (5849_CR62) 2014; 11 5849_CR48 5849_CR46 M Coakley (5849_CR50) 2012; 21 5849_CR45 MH Andreae (5849_CR61) 2017; 42 RP Amorrortu (5849_CR68) 2018; 19 ME Ford (5849_CR47) 2013; 38 SF Wallington (5849_CR41) 2016; 50 AJ Smorenburg (5849_CR70) 2014; 32 J Cunningham-Erves (5849_CR23) 2020; 20 MV Rivera-Goba (5849_CR36) 2011; 22 CO Ezeugwu (5849_CR39) 2011; 103 A Napoles (5849_CR63) 2017; 133 SA Adams (5849_CR56) 2015; 40 SL Goff (5849_CR44) 2016; 3 S Dawson (5849_CR8) 2018; 21 A Heiat (5849_CR5) 2002; 162 MA Le Rouzic (5849_CR21) 2020; 37 G Alahmad (5849_CR37) 2018; 25 |
| References_xml | – volume: 13 start-page: 319 issue: 3 year: 2016 ident: 5849_CR64 publication-title: Clin Trials doi: 10.1177/1740774516631735 – volume: 8 start-page: 214 issue: 2 year: 2011 ident: 5849_CR52 publication-title: Clin Trials doi: 10.1177/1740774510396742 – volume: 13 start-page: 445 issue: 3 year: 2019 ident: 5849_CR66 publication-title: J Diabetes Sci Technol doi: 10.1177/1932296819839503 – volume: 18 issue: 10 year: 2016 ident: 5849_CR69 publication-title: J Med Internet Res. doi: 10.2196/jmir.6515 – volume: 162 start-page: 1682 issue: 15 year: 2002 ident: 5849_CR5 publication-title: Arch Intern Med doi: 10.1001/archinte.162.15.1682 – volume: 31 start-page: 373 issue: 5 year: 2014 ident: 5849_CR26 publication-title: Drugs Aging doi: 10.1007/s40266-014-0168-2 – volume: 82 start-page: 84 issue: 4 year: 2020 ident: 5849_CR7 publication-title: J Infect doi: 10.1016/j.jinf.2020.11.004 – ident: 5849_CR53 doi: 10.1089/jwh.2010.2504 – volume: 133 start-page: 77 year: 2017 ident: 5849_CR63 publication-title: Adv Cancer Res doi: 10.1016/bs.acr.2016.08.004 – ident: 5849_CR33 – volume: 50 start-page: 111 issue: 1 year: 2016 ident: 5849_CR41 publication-title: Am J Prev Med doi: 10.1016/j.amepre.2015.07.036 – volume: 395 start-page: 1955 issue: 10242 year: 2020 ident: 5849_CR1 publication-title: Lancet. doi: 10.1016/S0140-6736(20)31380-5 – ident: 5849_CR28 doi: 10.1093/cid/ciu726 – volume: 19 start-page: 862 issue: 1 year: 2019 ident: 5849_CR24 publication-title: BMC Health Serv Res doi: 10.1186/s12913-019-4721-x – volume: 25 start-page: 107327481877372 issue: 1 year: 2018 ident: 5849_CR37 publication-title: Cancer Control doi: 10.1177/1073274818773720 – volume: 23 start-page: 1016 issue: 9 year: 2018 ident: 5849_CR72 publication-title: Oncologist doi: 10.1634/theoncologist.2018-0033 – volume: 22 start-page: 118 issue: 1 year: 2017 ident: 5849_CR17 publication-title: J Deaf Stud Deaf Educ doi: 10.1093/deafed/enw066 – volume: 37 start-page: 500 issue: 6 year: 2020 ident: 5849_CR21 publication-title: Pediatr Hematol Oncol doi: 10.1080/08880018.2020.1759738 – volume: 126 start-page: 1077 issue: 5 year: 2020 ident: 5849_CR29 publication-title: Cancer doi: 10.1002/cncr.32487 – volume: 36 start-page: 111 issue: 3 year: 2018 ident: 5849_CR32 publication-title: J Vasc Nurs doi: 10.1016/j.jvn.2018.03.003 – volume: 326 start-page: 1244 issue: 7401 year: 2003 ident: 5849_CR3 publication-title: BMJ. doi: 10.1136/bmj.326.7401.1244 – volume: 33 start-page: 925 issue: 5 year: 2012 ident: 5849_CR59 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2012.06.005 – volume: 21 start-page: 713 issue: 7 year: 2012 ident: 5849_CR50 publication-title: J Womens Health (Larchmt) doi: 10.1089/jwh.2012.3733 – volume: 19 start-page: 115 issue: 1 year: 2018 ident: 5849_CR68 publication-title: Trials doi: 10.1186/s13063-018-2507-9 – volume: 17 start-page: 607 issue: 1 year: 2016 ident: 5849_CR35 publication-title: Trials doi: 10.1186/s13063-016-1724-3 – volume: 16 start-page: 43 issue: 1 year: 2016 ident: 5849_CR25 publication-title: BMC Womens Health doi: 10.1186/s12905-016-0319-1 – volume: 103 start-page: 839 issue: 9-10 year: 2011 ident: 5849_CR39 publication-title: J Natl Med Assoc doi: 10.1016/S0027-9684(15)30438-7 – ident: 5849_CR48 doi: 10.1186/1475-9276-12-44 – volume: 11 start-page: 167 issue: 2 year: 2014 ident: 5849_CR62 publication-title: Clin Trials doi: 10.1177/1740774513518849 – volume: 12 start-page: 45 issue: 1 year: 2015 ident: 5849_CR57 publication-title: Clin Trials doi: 10.1177/1740774514556551 – volume: 17 start-page: 1180 issue: 9 year: 2012 ident: 5849_CR27 publication-title: Oncologist doi: 10.1634/theoncologist.2011-0384 – volume: 23 start-page: 100404 year: 2020 ident: 5849_CR10 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100404 – volume: 38 start-page: 29 issue: 1 year: 2013 ident: 5849_CR47 publication-title: Health Soc Work doi: 10.1093/hsw/hlt001 – volume: 3 start-page: 731 issue: 4 year: 2016 ident: 5849_CR44 publication-title: J Racial Ethn Health Disparities doi: 10.1007/s40615-015-0192-x – volume: 46 start-page: 2232 issue: 8 year: 2015 ident: 5849_CR19 publication-title: Stroke doi: 10.1161/STROKEAHA.114.008564 – volume: 15 start-page: e289 issue: 4 year: 2019 ident: 5849_CR40 publication-title: J Oncol Pract doi: 10.1200/JOP.18.00638 – ident: 5849_CR45 doi: 10.2105/AJPH.2009.162982 – volume: 124 start-page: 95 issue: 1 year: 2018 ident: 5849_CR65 publication-title: Cancer doi: 10.1002/cncr.30935 – volume: 24 start-page: e1351 issue: 12 year: 2019 ident: 5849_CR31 publication-title: Oncologist doi: 10.1634/theoncologist.2019-0166 – volume: 22 start-page: 295 issue: 4 year: 2011 ident: 5849_CR36 publication-title: J Assoc Nurses AIDS Care doi: 10.1016/j.jana.2010.10.007 – volume: 21 start-page: 694 issue: 1 year: 2020 ident: 5849_CR11 publication-title: Trials doi: 10.1186/s13063-020-04613-7 – volume: 15 start-page: 1392 issue: 11 year: 2017 ident: 5849_CR20 publication-title: J Natl Compr Canc Netw doi: 10.6004/jnccn.2017.7005 – volume: 35 start-page: 13 issue: 2 year: 2013 ident: 5849_CR30 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2013.03.007 – volume: 16 start-page: 80 issue: 1 year: 2015 ident: 5849_CR74 publication-title: Trials doi: 10.1186/s13063-015-0582-8 – volume: 32 start-page: 2989 issue: 25 year: 2014 ident: 5849_CR70 publication-title: Vaccine doi: 10.1016/j.vaccine.2014.03.081 – volume: 18 start-page: 23 issue: 1 year: 2020 ident: 5849_CR73 publication-title: Behav Sleep Med doi: 10.1080/15402002.2018.1518230 – volume: 37 start-page: 324 issue: 5 year: 2011 ident: 5849_CR54 publication-title: Am J Drug Alcohol Abuse. doi: 10.3109/00952990.2011.596973 – volume: 23 start-page: 159 issue: 1 year: 2020 ident: 5849_CR12 publication-title: Health Expect doi: 10.1111/hex.12984 – volume: 89 start-page: 327 issue: 3 year: 2003 ident: 5849_CR4 publication-title: Heart doi: 10.1136/heart.89.3.327 – volume: 21 start-page: 3 issue: 1 year: 2018 ident: 5849_CR8 publication-title: Health Expect doi: 10.1111/hex.12597 – volume: 21 issue: 11 year: 2019 ident: 5849_CR51 publication-title: J Med Internet Res doi: 10.2196/14203 – volume: 16 start-page: e0251685 issue: 5 year: 2021 ident: 5849_CR9 publication-title: PLOS ONE doi: 10.1371/journal.pone.0251685 – volume: 47 start-page: 1363 issue: 3 Pt 2 year: 2012 ident: 5849_CR55 publication-title: Health Serv Res doi: 10.1111/j.1475-6773.2012.01386.x – volume: 11 start-page: 486 issue: 6 year: 2015 ident: 5849_CR38 publication-title: J Oncol Pract doi: 10.1200/JOP.2015.005934 – ident: 5849_CR46 doi: 10.1097/QAI.0000000000001085 – volume: 9 start-page: 114 issue: 1 year: 2018 ident: 5849_CR58 publication-title: Appl Clin Inform doi: 10.1055/s-0038-1625964 – volume: 39 start-page: 169 issue: 2 year: 2014 ident: 5849_CR49 publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2014.08.004 – volume: 10 start-page: 949 issue: 6 year: 2013 ident: 5849_CR67 publication-title: Clin Trials doi: 10.1177/1740774513494880 – volume: 9 start-page: 333 issue: 3 year: 1999 ident: 5849_CR6 publication-title: Ethn Dis – volume: 17 start-page: 263 issue: 1 year: 2016 ident: 5849_CR15 publication-title: Trials doi: 10.1186/s13063-016-1384-3 – volume: 20 start-page: 840 issue: 1 year: 2020 ident: 5849_CR23 publication-title: BMC Public Health doi: 10.1186/s12889-020-08939-4 – volume: 34 start-page: 399 issue: 9 year: 2020 ident: 5849_CR13 publication-title: AIDS Patient Care STDS doi: 10.1089/apc.2020.0008 – volume: 27 start-page: 467 issue: 2 year: 2019 ident: 5849_CR60 publication-title: Support Care Cancer doi: 10.1007/s00520-018-4337-4 – volume: 34 start-page: 116 issue: 1 year: 2014 ident: 5849_CR14 publication-title: Med Decis Making doi: 10.1177/0272989X13497264 – volume: 9 start-page: 188 issue: 2 year: 2012 ident: 5849_CR71 publication-title: Clin Trials doi: 10.1177/1740774512436881 – volume: 44 start-page: 148 issue: 5 year: 2019 ident: 5849_CR22 publication-title: Curr Probl Cardiol doi: 10.1016/j.cpcardiol.2018.11.002 – volume: 33 start-page: 604 issue: 4 year: 2011 ident: 5849_CR16 publication-title: J Public Health (Oxf) doi: 10.1093/pubmed/fdq100 – volume: 185 start-page: 195 year: 2015 ident: 5849_CR42 publication-title: J Affect Disord doi: 10.1016/j.jad.2015.06.046 – volume: 40 start-page: 251 issue: 2 year: 2015 ident: 5849_CR56 publication-title: J Community Health doi: 10.1007/s10900-014-9924-9 – volume: 42 start-page: 77 year: 2017 ident: 5849_CR61 publication-title: J Clin Anesth doi: 10.1016/j.jclinane.2017.08.014 – volume: 21 start-page: 2364 issue: 10 year: 2019 ident: 5849_CR43 publication-title: Genet Med doi: 10.1038/s41436-019-0498-x – ident: 5849_CR2 – ident: 5849_CR18 doi: 10.1177/1363459320963431 – volume: 29 start-page: 23 issue: 1 year: 2019 ident: 5849_CR34 publication-title: Ethn Dis doi: 10.18865/ed.29.1.23 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.615226 |
| SecondaryResourceType | review_article |
| Snippet | Background
Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite... Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite... Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack... BackgroundWithout inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite... Abstract Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world.... |
| SourceID | doaj pubmedcentral proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 880 |
| SubjectTerms | Access to education Biomedicine Chronic illnesses Clinical research Clinical trial Clinical trials Communication Coronaviruses COVID-19 Demographic aspects Diversity Equality Ethnicity Health care disparities Health Sciences Inclusion Language Management Medical research Medicine Medicine & Public Health Methodology Minority & ethnic groups Older people Pandemics Statistics for Life Sciences Systematic review |
| SummonAdditionalLinks | – databaseName: Nursing & Allied Health Database dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQYgLb0SgICMhcYCoSfxKTqggKi5UFQLUmxU_0q60JNvNbs_8CH4hv4Sx46QKFb1wi2JbsTOfZ8aeF8CroqobWudFalnRpKjfZim-4WmpUVxzpi11NhSbkIeH5fFxdRQv3ProVjnyxMCobWf8HfleUXrhj-p99m51lvqqUd66GktoXIcbudeNEc_yy_fJiiBLwcZAmVLs9civg9USD9Aod6tUzoRRyNl_mTNf9pb8y2QaJNHB3f9dwz24E3VQsj-A5j5cc-0DuPU5WtkfwunR4KPXnpBFa5Zbf6GGT2SMoiSh1Ef_--evmqzr1cKSIQCGdA1BfZIsp1TNpG59I87uh4vVm3qCajIZwikewbeDj18_fEpjRYbU4A_bpDwzkmqtWUmNrBzVlLlG44mn4YajLuK4LWzNDIo9SZkwTNjcWo4wKPHU6zL6GHbarnVPgDTO1rluZCG0YTkOQbGIyiu1tKHc0SyBfCSNMjFdua-asVTh2FIKNZBTITlVIKeSCbyZxqyGZB1X9n7vKT719Im2w4tufaLivlVO21zgenMfICyYKB315bork5taUy4SeO3xojw7wOmZOkY14CJ9Yi21LxCDyBYZT2B31hO3sZk3j5hRkY306gIwCbycmv1I7xrXum6LfYTn0pyyIgE5Q-psZfOWdnEaUonj15GpswTejpi--Pi__9zTq-f6DG4XfpN5px-2Czub9dY9h5vmfLPo1y_CFv0DfMVEIw priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQwcAQFIS68EYGCjITEASI28SPOsSAqLlQVL_VmxY-0Ky3ZarPbcz-CL-RLmHGcRaGABLcoHiv2eJ7xPACelXXT8qYocy_KNkf7dpbjG5lri-paCut58LHZRHVwoI-O6sOUFNaP0e7jlWSU1JGttXrVo7SNd47o_qLWrPPqMlxBdaepYcOHj19G-YsalosxPea38yYqKFbqvyiPL8ZI_nJRGvXP_s3_W_ktuJHsTbY3EMhtuBS6O3DtfbpRvwsnh0M8XnfM5p1bbOjnGT6xMWOSxbYe_ffzbw1bNadzz4ZkF7ZsGdqObLEty8yajgZxSV9D6tTUMzSJ2ZA6cQ8-77_99OZdnrov5A4Xuc7lzFXcWis0d1UduOUitBa9m1Y6iXZHkL70jXCo4ioulBPKF95LPHKNHm6Y8fuw0y278ABYG3xT2LYqlXWiwCmoAtFQ5Z63XAY-y6AYD8S4VJqcOmQsTHRRtDIDCg2i0EQUmiqDF9s5p0Nhjr9Cv6Zz3kJSUe34Yrk6NolHTbC-ULjfgpKBlVA6cGrNXbvCNZZLlcFzohJDrI_Lc03KYMBNUhEts6e0IhEoZAa7E0hkWTcdHunMJJHRm1KTdYv-K6Lj6XaYZlIYXBeWG4RRJJElF2UG1YQ-JzubjnTzk1g2HL-OAlxk8HKk0p8f_zPmHv4b-CO4XhKhU8CP2IWd9WoTHsNVd7ae96snkVF_AB6lOjk priority: 102 providerName: Springer Nature |
| Title | Promoting inclusion in clinical trials—a rapid review of the literature and recommendations for action |
| URI | https://link.springer.com/article/10.1186/s13063-021-05849-7 https://www.proquest.com/docview/2812328710 https://www.proquest.com/docview/2607305342 https://pubmed.ncbi.nlm.nih.gov/PMC8643184 https://doaj.org/article/ebd16b48106946468e312499c1cab356 |
| Volume | 22 |
| WOSCitedRecordID | wos000726280200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: Open Access资源_DOAJ customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LjtMwcAQLQlwQTxFYKiMhcYBom_iVHHdRV3BoFRVYlZMVP8JWKumqaTkiPoIv5EsYO0khrIALF6v1Q4lnxvOI5wHwLM3LipZJGluWVjHqt-MYe3icaRTXnGlLnQ3FJuRsli0WefFLqS_vE9amB24Bd-S0TYRmWeIjNAUTmaO-XnJuElNqykOy7bHMe2Oq5cEoZSnrQ2QycdQgpw73lWg6o8TNYzkQQyFb_2WefNlP8rfL0iCDTm_DrU55JMftS9-BK66-Czem3fX4PTgvWue6-iNZ1ma181_C8Bfpwx9JqNHRfP_6rSSb8mJpSRu5QtYVQUWQrPY5lklZ-0Ekx0-uK7vUENRvSRsHcR_en07evXodd6UUYoP73cZ8bCTVGuFIjcwd1ZS5SqOpUnHDUYlw3Ka2ZAbllaRMGCZsYi1H_GVorroxfQAH9bp2D4FUzpaJrmQqtGEJLkF5hlontbSi3NFxBEkPWWW6POO-3MVKBXsjE6rFhkJsqIANJSN4sV9z0WbZ-OvsE4-w_UyfITt0IN2ojm7Uv-gmguce3cqfY3w9U3bhCLhJnxFLHYtMeH7GeASHg5l4_sxwuCcY1Z3_RqWZV1XRGEVwPN0P-5Xep6126x3OEZ69csrSCOSA0AY7G47Uy_OQAxyfjtyYRfCyJ8mfD_8z5B79D8g9hpupP0nep4cdwsF2s3NP4Lr5vF02mxFclfMz3y5kaLMRXDuZzIr5KJxQbKdfJthXvJkWH_Df_O3ZD699PW0 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALb9RAASOBOEDUTfzKHhAqj6pV21UPRdqbGz_SrrTNLptdEDd-BL-DH8UvYewkW4WK3nrgFsV2nHHG883E8wB4kfbzguZJGluWFjHqt70Y7_A40wjXnGlLnQ3FJuRgkA2H_YMV-NXGwni3ylYmBkFtJ8b_I99IMw_-qN733k2_xL5qlD9dbUto1Gyx675_Q5OtervzEb_vyzTd-nT4YTtuqgrEBsF2HvOekVRrzTJqZN9RTZkrNGrtBTcc8dRxm9qcGRTdkjJhmLCJtRxJydBycz2Kz70CV1GOS2_syeHSwEtkJlgbmJOJjQrxIZySosGOU_dj2QG_UCPgPBKc987864g2IN_W7f9tze7ArUbHJpv1prgLK668B9f3Gy-C-3ByUPsglsdkVJrxwv8wxCvSRomSUMqk-v3jZ05m-XRkSR3gQyYFQX2ZjJepqEle-kZcjVPXVKeqCJoBpA4XeQCfL4XOh7BaTkq3BqRwNk90IVOhDUtwCMI-KufU0oJyR3sRJC0rKNOkY_dVQcYqmGWZUDX7KGQfFdhHyQheL8dM62QkF_Z-7zls2dMnEg83JrNj1cgl5bRNBNKb-ABowUTmqC9H3jeJyTXlIoJXnj-VF3f4eiZvojaQSJ84TG0K5HkU-4xHsN7piWLKdJtbHlWNmKzUGYNG8HzZ7Ed617_STRbYR3gU4pSlEcjOzuhQ1m0pRychVTrOjqDFInjT7qGzyf-9co8uftdncGP7cH9P7e0Mdh_DzdRvcO_gxNZhdT5buCdwzXydj6rZ0yAeCBxd9t76A2Q9n_4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VFFVceCNcCiwSiANYifdl54BQoUREpVEOIJXT1vtwGyk4aZyAuPEj-DX8HH4Js36kMhW99cDN8u56veuZ-Wa88wB4SvtpxtKIhpbTLET9thfiHREmGuFacG2Zs2WxiXg0Sg4P--MN-NXEwni3ykYmloLazoz_R96liQd_VO973ax2ixjvDV7PT0NfQcqftDblNCoS2Xffv6H5Vrwa7uG3fkbp4N3Ht-_DusJAaBB4l6HomZhprXnCTNx3TDPuMo0afCaMQGx1wlKbcoNiPGZcGi5tZK3AZSVoxbkew-degU1UyTntwOZ4eDD-vD7DiBPJmzCdRHYLRIvyzBTNd5y8H8YtKCwrBpzHhfO-mn8d2JY4OLjxP-_gTbhea99kt2KXW7Dh8tuwdVD7F9yBk3HlnZgfk0lupiv_KxGvSBM_SsoiJ8XvHz9TskjnE0uq0B8yywhq0mS6TlJN0tw34s58cXXdqoKggUCqQJK78OlS1nkPOvksd_eBZM6mkc5iKrXhEQ5BhQDVdmZZxoRjvQCihiyUqRO1-3ohU1UabIlUFSkpJCVVkpKKA3ixHjOv0pRc2PuNp7Z1T59ivLwxWxyrWmIpp20kcb2RD42WXCaO-ULlfROZVDMhA3juaVV5QYivZ9I6ngMX6VOKqV2J9I-AwEUAO62eKMBMu7mhV1UL0EKdEWsAT9bNfqR3CszdbIV9pMcnwTgNIG5xSWtl7ZZ8clImUcfZEc54AC8bfjqb_N87t33xuz6GLWQp9WE42n8A16jnde_5xHegs1ys3EO4ar4uJ8XiUS0rCBxdNnP9AfdSqk0 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Promoting+inclusion+in+clinical+trials%E2%80%94a+rapid+review+of+the+literature+and+recommendations+for+action&rft.jtitle=Trials&rft.au=Bodicoat%2C+Danielle+H.&rft.au=Routen%2C+Ash+C.&rft.au=Willis%2C+Andrew&rft.au=Ekezie%2C+Winifred&rft.date=2021-12-04&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=22&rft_id=info:doi/10.1186%2Fs13063-021-05849-7&rft_id=info%3Apmid%2F34863265&rft.externalDocID=PMC8643184 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |